Device type · JXM
Enzyme Immunoassay, Benzodiazepine
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
JXM
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
10
510(k), De Novo and PMA
Adverse event reports
2
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Benzodiazepine
- Product code
- JXM
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3170
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for JXM
Latest FDA decisions
The 8 newest of 10 since 2015.
K243498 · Decided Dec 11, 2024 · 29 days after receipt
Device type: Enzyme Immunoassay, Benzodiazepine (JXM) · Laboratory Medicine & Pathology
K221765 · Decided Dec 23, 2022 · 189 days after receipt
Device type: Enzyme Immunoassay, Benzodiazepine (JXM) · Laboratory Medicine & Pathology
K190968 · Decided Dec 9, 2019 · 241 days after receipt
Device type: Enzyme Immunoassay, Benzodiazepine (JXM) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
Reports received
2
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
2
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 1 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 2 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 1 | 0 | 0 | 0 |
| Nov 24 | 2 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 1 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 2 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 1 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- False Negative Result2
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions2
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2876-2020 · Started Jul 13, 2020
Reason given: Incorrect lot number for Standard Oral Fluid Negative Calibrator on specification sheet included in kit and/or additionally same error on unit box
Cause as FDA categorized it: Under Investigation by firm
Z-2877-2020 · Started Jul 13, 2020
Reason given: Incorrect lot number for Standard Oral Fluid Negative Calibrator on specification sheet included in kit and/or additionally same error on unit box
Cause as FDA categorized it: Under Investigation by firm
- 1 Step 12 Panel Cup, Item No. NBCA-12M-WTerminated
Z-0484-2016 · Started Nov 16, 2015
Reason given: Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and...
Cause as FDA categorized it: Nonconforming Material/Component
78 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.